In rodent studies, the introduction of a gain-of-function SGK1 mutation intensified both hepatic steatosis and fibrotic responses, while CYP11B2 deficiency protected against MASLD in animals with constitutive SGK1 activation [25,40]. The gene discussed is SGK1; the disease is fatty liver disease.